Remove bioscience
article thumbnail

INTEGRA Biosciences Drives Down Transport Emissions with European Production Facility

i4.0 today

INTEGRA Biosciences has completed construction of its new campus and pipette tip manufacturing plant at its headquarters in Zizers, Switzerland. Ursula Leuthold, Sustainability Coordinator for INTEGRA Biosciences , said: “We are dedicated to a proactive and company-wide approach to sustainability. Today Magazine.

article thumbnail

How Yield10 Bioscience Plans to Grow the PHA Bioplastic Market

Plastics Today

The agricultural bioscience company is developing oilseed Camelina as a platform crop for large-scale production of low-carbon polyhydroxyalkanoate biopolymers.

111
111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

$40m rolled out to foster NSW’s innovative bioscience startups

AU Manufacturing

The New South Wales government is backing local biosciences startups in their efforts to develop and commercialise their problem-solving technology with a new $40 million funding. . The post $40m rolled out to foster NSW’s innovative bioscience startups appeared first on Australian Manufacturing.

article thumbnail

Willow Biosciences Inc. announces investment from Kalsec

Canadian Manufacturing

CALGARY — Willow Biosciences Inc., a biotechnology company focused on improving industrial manufacturing of functional ingredients, announces a strategic investment from Kalsec® Inc.,

article thumbnail

INTEGRA Biosciences and MACHEREY-NAGEL Partner to Automate NucleoSpin® Nucleic Acid Purification Kits

i4.0 today

INTEGRA Biosciences has collaborated closely with nucleic acid extraction experts MACHEREY-NAGEL (MN) to develop automated protocols for a variety of NucleoSpin ® RNA and DNA extraction and purification kits on the ASSIST PLUS pipetting robot. Visit the INTEGRA Biosciences website to learn more. About INTEGRA Biosciences.

article thumbnail

Liminal BioSciences provides R&D update

Canadian Manufacturing

LAVAL — Liminal BioSciences has nominated a lead preclinical candidate, LMNL6326, for the development of its OXER1 antagonist program, targeting the treatment of eosinophil-driven diseases. ” Eosinophil-driven diseases (EDD) such as eosinophilic asthma and atopic dermatitis represent a significant area of unmet need in global health.

article thumbnail

Amerigo Scientific and OZ Biosciences Announce Distribution Agreement for PolyMag CRISPR Kit

Manufacturing Tomorrow

Amerigo Scientific and OZ Biosciences announced the distribution agreement for PolyMag CRISPR Kit for gene editing experiments with high transfection efficiency and low cell toxicity.

40